Ketanserin treatment, by preventing the enhanced expression of calcineurin and Prkcb1, may serve to ameliorate the enhanced vulnerability to chronic stress-evoked pathology and the increased 5-HT2 receptor function in MS animals. Here, PRKCB is linked to myeloid sarcoma.